Luna TMVR System
Pre-clinical- Indications
- Mitral regurgitation
Company intelligence / Profile preview
Tioga Cardiovascular has developed the Luna™ transcatheter mitral valve replacement (TMVR) system. In October 2024, the company announced successful first-in-human implantations of its Luna TMVR system in Paraguay and Georgia. The initial patients achieved excellent hemodynamics post-procedure, marking a significant milestone for this next-generation minimally invasive device targeting complex cases of mitral regurgitation. The company is advancing toward broader clinical experience and further product development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tioga Cardiovascular.